Proportion of PR1-specific CTLs from peripheral blood of CML patients under imatinib or IFN-α therapy
| Patient . | Sex . | Stage . | Type of treatment . | Treatment period (mo) . | Response Type* . | HLA type . | PR1-CTLs, %† . |
|---|---|---|---|---|---|---|---|
| UPN 19 | F | CP | Imatinib | 18 | hCR | A*0201 | ND |
| UPN 20 | M | CP | Imatinib | 12 | hCR | A*0201 | ND |
| UPN 21 | M | CP | Imatinib | 9 | hCR | A*0201 | ND |
| UPN 22 | F | CP | Imatinib | 12 | hCR | A*0201 | ND |
| UPN 23 | M | CP | Imatinib | 20 | hCR | A*0201 | 0.102 |
| UPN 24 | M | CP | Imatinib | 11 | MR | A*0201 | ND |
| UPN 25 | F | CP | Imatinib | 10 | hCR | A*0201 | ND |
| UPN 26 | F | CP | Imatinib | 15 | hCR | A*0201 | ND |
| UPN 27 | F | CP | Imatinib | 8 | CR | A*0201 | 0.1 |
| UPN 28 | M | CP | Imatinib | 9 | MR | A*0201 | ND |
| UPN 29 | M | CP | Imatinib | 21 | CR | A*0201 | ND |
| UPN 30 | F | CP | IFN-α | NA | hCR | A*0201 | 0.506 |
| UPN 31 | M | CP | IFN-α | 60 | hCR | A*0201 | 0.23 |
| UPN 32 | M | CP | IFN-α | 6 | hCR | A*0201 | 6.25 |
| UPN 33 | F | CP | IFN-α | 12 | hCR | A*0201 | 0.12 |
| Patient . | Sex . | Stage . | Type of treatment . | Treatment period (mo) . | Response Type* . | HLA type . | PR1-CTLs, %† . |
|---|---|---|---|---|---|---|---|
| UPN 19 | F | CP | Imatinib | 18 | hCR | A*0201 | ND |
| UPN 20 | M | CP | Imatinib | 12 | hCR | A*0201 | ND |
| UPN 21 | M | CP | Imatinib | 9 | hCR | A*0201 | ND |
| UPN 22 | F | CP | Imatinib | 12 | hCR | A*0201 | ND |
| UPN 23 | M | CP | Imatinib | 20 | hCR | A*0201 | 0.102 |
| UPN 24 | M | CP | Imatinib | 11 | MR | A*0201 | ND |
| UPN 25 | F | CP | Imatinib | 10 | hCR | A*0201 | ND |
| UPN 26 | F | CP | Imatinib | 15 | hCR | A*0201 | ND |
| UPN 27 | F | CP | Imatinib | 8 | CR | A*0201 | 0.1 |
| UPN 28 | M | CP | Imatinib | 9 | MR | A*0201 | ND |
| UPN 29 | M | CP | Imatinib | 21 | CR | A*0201 | ND |
| UPN 30 | F | CP | IFN-α | NA | hCR | A*0201 | 0.506 |
| UPN 31 | M | CP | IFN-α | 60 | hCR | A*0201 | 0.23 |
| UPN 32 | M | CP | IFN-α | 6 | hCR | A*0201 | 6.25 |
| UPN 33 | F | CP | IFN-α | 12 | hCR | A*0201 | 0.12 |
CP indicates chronic phase of CML; ND, not detectable (< 0.02% [less than 1 PR1+/CD8+ cell in 5.000 CD8+ cells]); NA, not available. For other abbreviations, see Table 1 footnote.
Responses defined as in Table 1 footnote with the addition of complete hematological remission (hCR), indicated by normal peripheral blood differential.
PR1-CTL percentage defined as the percentage of CD8+ lymphocytes that label with both anti-CD8 (FITC) and PR1-HLA-A2 tetramer (PE). An hCR does not exclude a better overall response (major or complete cytogenetic response), as a cytogenetic diagnostic was not always available at the time of PR1-CTL measurement.